This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
After the market closed on June 11, Selecta Biosciences, Inc. (NASDAQ:SELB) announced it had entered a licensing deal with $SOBI (STO:SOBI), granting most of the global rights to Selecta’s phase III gout drug, SEL-212, to SOBI. Selecta’s stock fell about […]
This content is for members only
Last Friday, the FDA granted emergency use authorization (EUA) to Gilead Sciences, Inc. (NASDAQ:GILD) remdesivir to treat patients hospitalized with COVID19. The EUA approval came within days after Gilead and NIH scientists released clinical study results demonstrating the statistical significance […]